==== Front J Diabetes Res J Diabetes Res JDR Journal of Diabetes Research 2314-6745 2314-6753 Hindawi 10.1155/2023/8542262 Research Article Short-Term Effect of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection in Perioperative Patients with Type 2 Diabetes Mellitus Song Wei 1 Wen Jianxuan 1 Zhang Jinming 1 Luo Meng 2 Hu Yue 3 https://orcid.org/0000-0003-3680-6711 Zhang Yu 3 https://orcid.org/0000-0002-2711-3481 Fan Guanjie fanguanjie@gzucm.edu.cn 1 https://orcid.org/0000-0002-8007-8128 Zhao Ling lindazhao@gzucm.edu.cn 1 1The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510210 Guangdong Province, China 2Department of Endocrinology, Huizhou Hospital of Guangzhou, University of Chinese Medicine, Huizhou, 516000 Guangdong Province, China 3Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510120 Guangdong Province, China Academic Editor: Mark Yorek 2023 23 6 2023 2023 854226223 12 2022 5 6 2023 10 6 2023 Copyright © 2023 Wei Song et al. 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background Hyperglycemia is common and difficult to control in perioperative patients with type 2 diabetes mellitus (T2DM), which impacts their prognosis after operation. Our study investigated the short-term effect of continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI) in perioperative T2DM patients using the data envelopment analysis (DEA). Methods T2DM patients (n = 639) who underwent surgeries in Guangdong Provincial Hospital of Traditional Chinese Medicine (2009.01-2017.12) were included. Insulin was provided to each patient during the study and separated into a CSII group (n = 369) and an MDI group (n = 270). DEA was performed to compare the therapeutic indexes and investigate the short-term effect of the CSII group and MDI group. Results Scale efficiencies of the CSII group with CCR model and BCC model were better than that of the MDI group. Regarding slack variables, with higher surgical levels, the CSII group was closer to the ideal state than the MDI group, which indicated in improving the average fasting blood glucose (AFBG), antibiotic use days (AUD), preoperative blood glucose control time (PBGCT), first postoperative day fasting blood glucose (FPDFBG), and postoperative hospitalization days (PHD). Conclusion CSII could effectively control blood glucose levels and shorten perioperative hospitalizing time for T2DM patients, indicating that CSII was beneficial in perioperative period and should be promoted clinically. Guangdong Provincial Hospital of Traditional Chinese MedicineYN2020ZWB03 Basic and Applied Basic Research Foundation of Guangdong Province2021B1515120085 Guangdong Science and Technology Department2017ZC0159 National Research Program of China2019YFC1709301 ==== Body pmc1. Introduction Type 2 diabetes mellitus (T2DM) caused by abnormal blood sugar metabolism is a widely seen chronic disease that affects human health and quality of life. With living standard's improving and changes in living habits, the incidence rate has increased significantly [1]. In recent years, an increasing number of patients with T2DM have undergone surgery, but the hyperglycemic state associated with diabetes affects a patient's internal environment and physiological functions, enhances the likelihood of surgery and infection, and affects wound healing. Studies have pointed out that strict control of perioperative blood glucose in patients with T2DM can improve the effect of surgery and promote postoperative healing [2, 3]. Insulin therapy is the optimal treatment for perioperative patients with T2DM to control blood glucose [4], which includes continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI). CSII is a new type of glucose control instrument in clinical practice in recent years, which can mimic the physiology of insulin secretion in patients and continuously pumps insulin for patients to stabilize blood glucose levels. It has been reported that CSII effectively alleviated hyperglycemia in patients who had a suboptimal response to therapy for T2DM, which is more effective than MDI [5]. However, there is no study to evaluate which of the two methods of CSII or MDI is more beneficial in health economics. Data envelopment analysis (DEA), first proposed by Wei and Charnes et al., is a method to systematically evaluate the relative effectiveness of decision-making units of the same type according to specific input/output indexes. It is one of the operation research methods in comprehensive evaluation methods [6, 7]. DEA can evaluate the relative efficiency of treatment schemes with single or multiple input indexes and multiple output indexes and select more effective schemes from them. At the same time, it can analyze the inputs and outputs of relatively inefficient schemes, which is conducive to further improvement of inefficient schemes, so that each decision unit can obtain the best benefits. In recent years, DEA has gradually been used to evaluate the prevention and treatment of different chronic diseases, such as diabetes. Therefore, this study retrospectively analyzed the perioperative patient with T2DM in Guangdong Provincial Hospital of Traditional Chinese Medicine in the last 7 years and utilized DEA to investigate the clinical efficacy and health economic benefits of CSII and MDI in treating the perioperative patient with T2DM during perioperative period. 2. Materials and Methods 2.1. General Information The study included 639 patients with T2DM who had undergone surgery in our hospital from January 2009 to November 2017. According to the treatment plan, the patients were divided into a CSII group (n = 369) and an MDI group (n = 270). 2.1.1. Inclusion Criteria The inclusion criteria are as follows: Patients that were diagnosed with T2DM with the criteria established by WHO in 1999 All patients that had indications for surgery and were ready for surgery Patients that were treated with CSII or MDI 2.1.2. Exclusion Criteria The exclusion criteria are as follows: Patients with severe endocrine system, nervous system, immune system, or mental system diseases Patients with severe heart and lung dysfunction or severe liver and kidney dysfunction 2.2. Methods Baseline comparisons were performed between the two groups using SPSS 17.0, and the data are expressed as mean ± SD. If the quantitative data were normally distributed and the variances were equal, the data were analyzed with t-tests. If not, the data were evaluated by rank sum test. Qualitative data were assessed with chi-square test. In data envelopment analysis, the input indicators of both groups were the total hospitalization cost and hospitalization days. The output indicators were the average fasting blood glucose (AFBG), antibiotic use days (AUD), preoperative blood glucose control time (PBGCT), first postoperative day fasting blood glucose (FPDFBG), and postoperative hospitalization days (PHD). Each included patient in the decision-making unit was analyzed using the Charnes, Cooper, and Rhodes (CCR) model and the Banker, Charnes, and Cooper (BCC) model. The efficiency values of each decision-making unit were calculated with DEAP 2.1 software. The average value for each group was taken, and the average efficiency values of the two groups were compared. Then, two groups of slack variables were analyzed and compared to draw conclusions. 3. Results 3.1. Comparison of Patients' Baseline Characteristics No difference in sex, age, course of disease, or type of surgery between 2 groups was found. The HbA1c level in the CSII group was significantly higher than that of MDI group, suggesting that CSII group patients had higher blood glucose levels and worse condition than patients in the other group (Table 1). 3.2. Hospitalization Days and Hospitalization Costs Results indicated that no difference in the length of hospitalization between the 2 groups was shown. The total hospitalization cost in the CSII group was significantly higher than that of the MDI group (Table 2). Note: by t-test, no difference in hospitalization days, but a significant difference in total cost between 2 groups was found. CNY: Chinese Yuan. 3.3. Data Envelopment Analysis Results 3.3.1. Input-Output Indicators A total of 639 patients were treated as independent decision-making units. The input indicators of both groups were the total hospitalization cost and hospitalization days. The output indicators were PBGCT, AFBG, FPDFBG, AUD, and PHD. 3.3.2. Analysis of Efficiency Values in the Two Groups Input indicators and output indicators were collected for 639 patients who completed the study, and these data were analyzed using DEAP software. The average efficiency of the two groups was taken as the overall efficiency value. The results (Table 3) show that the efficiency values in the CSII group with CCR/BCC model were better than those of the MDI group. 3.3.3. Analysis of Slack Variables in the Two Groups The slack variable indicates the gap between actual and ideal output. The smaller the slack variable, the closer it is to ideal state. According to Table 4, we can conclude that the CSII group was closer to the ideal state than the MDI group in terms of improving AFBG, FPDFBG, AUD, and PHD, while the MDI group was closer to the ideal state than the CSII group in terms of PBGCT and FPDFBG. Note: BG: blood sugar. FBG: fasting blood sugar. 3.4. Stratified Analysis In China, surgery is allocated into 4 grades based on complexity, difficulty, and risk according to medical surgery grading management system by National Health Commission of the People's Republic of China (https://www.nhc.gov.cn/wjw/ywfw/201306/def185b8d52e48918cf7e12e43e956d6.shtml). Accordingly, surgeries of lower difficulty, simpler procedure, and lower risks are classified as grade I, while surgeries with the highest risks, the most complex procedure, and the greatest technical difficulty are classified as grade IV surgeries. The two groups of patients were stratified according to the above-mentioned four levels of surgery. The CSII group included 79 patients who underwent grade I surgery, 59 patients who underwent grade II surgery, 136 patients who underwent grade III surgery, and 95 patients who underwent grade IV surgery. The MDI group included 61 patients who underwent grade I surgery, 81 patients who underwent grade II surgery, 64 patients who underwent grade III surgery, and 64 patients who underwent grade IV surgery. 3.4.1. Grade I Surgery The comparison of patients undergoing grade I surgery between the two groups (Table 5) showed that the CSII group was closer to ideal state than the MDI group in terms of improving AFBG, FPDBG, AUD, and PHD, while the opposite result was found in terms of PBGCT and FPDFBG. 3.4.2. Grade II Surgery In terms of grade II surgery, the CSII group was closer to the ideal state in terms of improving PBGCT, AFBG, AUD, and PHD. However, the MDI group was better than the CSII group in terms of first postoperative day fasting blood glucose and first postoperative day average blood glucose (Table 6). 3.4.3. Grade III Surgery At the grade III surgery level, the CSII group was closer to the ideal state than the MDI group in terms of improving each output indicator (Table 7). 3.4.4. Grade IV Surgery At the grade IV surgery level, the results were the same as those for grade III surgery (Table 8). 4. Discussion Diabetes mellitus is a common chronic disease induced by many factors, and it drastically lowers patients' quality of life. Once patients begin to suffer from this disease, it is necessary to take drugs for a long time to control it, and the course of diabetes mellitus is very long. Even in the treatment process, chronic complications or target organ damage caused by hyperglycemia, which is especially obvious in elderly diabetic patients, easily occurs [8]. Long-term hyperglycemia will cause high glucose toxicity, which may lead to the suppression of leukocytes in patients, may affect the function of leukocytes, may weaken the body's immunity, and may reduce the body's resistance to the disease. These are the main reasons why diabetes patients are prone to infection [9]. In regard to surgery, a blood glucose concentration that is too high will also affect the function of endothelial cells in patients' bodies and will affect the synthesis of collagen, which induces poor wound healing and prolongs incision healing time [10, 11]. At the same time, hospitalization due to hyperglycemia will significantly increase the incidence of complications and death risk in patients. It will significantly increase the infection risk in surgical patients and prolong the healing time of surgical wounds, resulting in longer hospital stays and increased hospitalization costs [2, 3, 12]. Therefore, timely detection and systematic management of hospitalized hyperglycemia are of great significance to endocrinology and nonendocrinology departments. CSII and MDI are two common methods of hypoglycemic therapy in clinical use. Although MDI is economical and convenient, it is difficult to simulate the 24-hour physiological insulin secretion curve in patients. Patients' blood sugar concentrations fluctuate greatly, and the effect of blood glucose control is poor because the insulin level between meals is relatively higher than the normal level, while the corresponding peak insulin level after meals is relatively lower [13]. The insulin pump known as CSII mainly adopts the form of a basal dose and bonus dose to input insulin, allowing for intensive insulin therapy, which can achieve continuous insulin microinput for 24 hours according to the body's normal insulin secretion in order to stably control blood sugar and reduce risks of hyperglycemia and hypoglycemia [14]. CSII is widely used in treating type 1 diabetes, and study has also shown that CSII has a significant advantage in T2DM patients with poor control of blood glucose [15]. In the perioperative period, the use of CSII is more advantageous, which can help patients to achieve the target blood glucose quickly and shorten the preoperative preparation time [16]. Studies have shown that CSII in diabetic patients is the best choice for cost effectiveness, although the amount of insulin is more and the cost is higher, but the cost-effectiveness ratio and incremental cost-effectiveness ratio are both smaller [17]. For now, there are few studies on the health economics of CSII and MDI during the perioperative period. Therefore, further research is needed. The evaluation methods of health economics mainly include analysis of cost-effectiveness, cost utility, cost benefit, and cost minimization [18]. However, each method has its own advantages and limitations. For example, cost-effectiveness analysis might be adopted to evaluate multiple schemes, but quality-adjusted life years of patients are difficult to be fixed. DEA can comprehensively evaluate the curative effect and economic benefit of multiple programs, especially for multiple outputs, which is more advantageous. The comprehensive evaluation of treatment programs by using DEA will also bring us a more economical, effective, and close to clinical practice. Compared with traditional analysis methods, DEA has the following advantages. First, while evaluating the relative effectiveness of the program, DEA does not emphasize the consistency and singleness of the intervention measures and only requires that all decision-making units be of the same type. Secondly, while evaluating the relative effectiveness of the plan, DEA can also analyze the input and output of each plan group and point out whether the input and output are optimized, which will help us to further improve the treatment plan continuously so as to better serve patients [19, 20]. For instance, DEA has been adopted [21] to evaluate the efficiency and performance of prevention and treatment for chronic diseases such as diabetes in the United States, and they proposed several intervention plans for the inefficient states to maintain and improve statewide health care services for the American population. Zhang et al. [22] applied DEA to conduct economic comprehensive evaluation on input and output indexes of metformin enteric-coated tablets combined sulfonylureas (group A), acarbose combined insulin glargine (group B), and premixed insulin (group C), respectively. Data indicated that input and output of the premixed insulin group were optimized, while the other two groups needed to be improved. Our data revealed that HbA1c levels of the CSII group were significantly higher than that of MDI, but the number of hospitalization days was not increased. The use of CSII may account for this result, suggesting that CSII has better efficiency for rapidly lowering blood sugar in order to shorten the hospitalization stay. The total treatment expense of the CSII group was higher, which may be relevant with higher blood glucose level in patients. Through data envelopment analysis, the efficiency values in the CSII group with CCR/BCC model were better than those of the MDI group. From the analysis results of slack variables, the higher the surgical level, the closer the CSII group was to ideal state compared to the MDI group in terms of improving PBGCT, AFBG, FPDFBG, AUD, and PHD, suggesting that the application of CSII in surgery may have better benefits. CSII did not bring better economic and health benefits in grade I and II surgeries. The perioperative patients who undergo grade III and above surgeries will be suggested to be treated with CSII, which is more beneficial to blood sugar control and shorten hospitalization time, but it may not reduce the total hospitalization cost of patients. Subcutaneous insulin injections are still the most commonly used method of insulin delivery, despite their limitations such as fear of needles, bleeding, and fat atrophy, as well as the inconvenience of injection [23, 24]. As a result, researchers have been exploring alternative routes of administration and their effects on treatment outcomes. Studies have mainly focused on administering insulin through the ocular, nasal, buccal, oral, and dermal routes. Ocular administration, while simple to perform and taking advantage of the ocular tissues' immunosensitivity, has low bioavailability and slow absorption rates that require higher doses or absorption agents, which can cause irritation of the eye [25]. Alternatively, oral administration through an ingestible self-directing millimeter drug delivery device, developed by Abramson et al., shows high acceptance and convenience for patients [26]. However, the efficacy is limited due to barriers such as physical, chemical, and biological factors, requiring high doses of insulin for effectiveness. Insulin has a significant impact on the body's immune system. It exerts both an anti-inflammatory response and enhances the function of immune cells, potentially playing a crucial role in immune cell differentiation and development. Recent findings suggest that insulin may also shift the immune response from innate to adaptive during prolonged immune activation [27]. While insulin appears to enhance some immune functions, studies have demonstrated that insulin may also be proinflammatory by opposing the function of anti-inflammatory Treg cells. Furthermore, sustained inflammatory injury may inhibit insulin release through apoptosis. However, insulin treatment can promote glucose uptake by immune cells, and milder doses of insulin may actually enhance immune function. The duration of insulin exposure and the timing of response measurements may also impact immune cell phenotype and immune response [28]. Tsai et al. [29] used a mouse model with a T cell-specific conditional Insr knockdown, finding that Tregs isolated from hyperinsulinemic obese mice had an elevated expression of IFN-γ and inhibited IL-10 release. Additionally, while TNF-α treatment of 30 min β cells reduced insulin secretion, extended 24 h exposure attenuated insulin release from cultured β cells. Acknowledgments This work is supported by the National Research Program of China “Evidence-based evaluation of Maiguan Fukang tablet combined with Tangbi external washing prescription for removing blood stasis and dredging collaterals to prevent the occurrence of diabetic foot ulcer” (Grant No. 2019YFC1709301), Project of Guangdong Science and Technology Department (Grant No. 2017ZC0159), Basic and Applied Basic Research Foundation of Guangdong Province (Project No. 2021B1515120085), and Internal Hospital Special Project of Guangdong Provincial Hospital of Traditional Chinese Medicine (Project No. YN2020ZWB03). Data Availability The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request. Ethical Approval This study was approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine and complied with the guidelines outlined in the Declaration of Helsinki. Consent The written consent was received from all participants. Conflicts of Interest The authors declared that they have no conflicts of interest regarding this work. Authors' Contributions SW and JXW designed the experiments. JMZ, ML, and YH performed the experiments. YZ and GJF collected and analyzed the data. GJF and LZ drafted manuscript. All authors read and approved the final manuscript. Table 1 Patients' baseline characteristics. Group N X ± S P Age MDI group 270 62.91 ± 11.330 0.077 CSII group 369 61.96 ± 13.555 Course (months) MDI group 270 159.80 ± 145.79 0.126 CSII group 369 89.55 ± 97.38 Weight MDI group 270 61.942 ± 11.2950 0.3990 CSII group 369 62.246 ± 11.9811 HbA1c MDI group 270 8.280 ± 2.0847 0.0001 CSII group 369 10.579 ± 2.9034 Note: by chi-square test, P > 0.05, no difference in sex between 2 groups. Table 2 Comparison of hospitalization days and hospitalization costs. Group N X ± S P Hospitalization day (days) MDI group 270 16.04 ± 9.22 0.996 CSII group 369 16.79 ± 9.53 Total hospitalization cost (CNY) MDI group 270 27407.52 ± 18519.71 0.001 CSII group 369 44407.12 ± 49029.92 Table 3 Comparison of efficiency values. Group CCR model efficiency value (θ) BCC model efficiency value (θ) CSII group 0.762 0.820 MDI group 0.754 0.764 Overall efficiency value 0.704 0.689 Table 4 Analysis of slack variables in the two groups. Group Preoperative Postoperative day 1 Days of antibiotic use Postoperative hospitalization days BG control time Mean FBG FBG Mean BG CSII group 0.615 0.571 1.764 1.135 0.446 0.154 MDI group 0.091 1.585 1.496 1.305 0.557 0.219 Total mean 0.286 0.918 1.216 1.337 0.999 0.231 Table 5 Analysis of slack variables in patients undergoing grade I surgery. Group Preoperative Postoperative day 1 Days of antibiotic use Postoperative hospitalization days BG control time Mean FBG FBG Mean BG CSII group 0.112 0.504 0.329 0.678 0.010 0.128 MDI group 0.102 1.023 0.458 0.567 0.118 0.378 Total mean 0.100 0.638 0.328 0.704 0.020 0.286 Table 6 Analysis of slack variables in patients undergoing grade II surgery. Group Preoperative Postoperative day 1 Days of antibiotic use Postoperative hospitalization days BG control time Mean FBG FBG Mean BG CSII group 0.107 0.706 0.289 0.493 0.001 0.118 MDI group 0.112 1.102 0.276 0.387 0.109 0.295 Total mean 0.108 0.879 0.213 0.504 0.033 0.260 Table 7 Analysis of slack variables in patients undergoing grade III surgery. Group Preoperative Postoperative day 1 Days of antibiotic use Postoperative hospitalization days BG control time Mean FBG FBG Mean BG CSII group 0.201 0.509 0.649 0.968 0.097 0.100 MDI group 0.318 1.278 0.968 1.0233 0.182 0.225 Total mean 0.164 0.683 0.674 0.937 0.101 0.214 Table 8 Analysis of slack variables in patients undergoing grade IV surgery. Group Preoperative Postoperative day 1 Days of antibiotic use Postoperative hospitalization days BG control time Mean FBG FBG Mean BG CSII group 0.104 0.639 0.639 0.865 0.122 0.102 MDI group 0.237 1.284 0.802 0.928 0.168 0.184 Total mean 0.109 0.821 0.694 0.937 0.105 0.132 ==== Refs 1 Yang W. Lu J. Weng J. Prevalence of diabetes among men and women in China The New England Journal of Medicine 2010 362 12 1090 1101 10.1056/NEJMoa0908292 2-s2.0-77950263954 20335585 2 Swanson C. M. Potter D. J. Kongable G. L. Cook C. B. Update on inpatient glycemic control in hospitals in the United States Endocrine Practice 2011 17 6 853 861 10.4158/EP11042.OR 2-s2.0-84855836146 21550947 3 ACE/ADA Task Force on Inpatient Diabetes American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control Diabetes Care 2006 29 8 1955 1962 10.2337/dc06-9913 2-s2.0-33746653814 16873812 4 Chinese Diabetes Society Chinese guideline for type 2 diabetes (2017) Chinese Journal of Diabetes Mellitus 2018 10 4 67 5 Aronson R. Reznik Y. Conget I. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial Diabetes, Obesity & Metabolism 2016 18 5 500 507 10.1111/dom.12642 2-s2.0-84961813392 26854123 6 Wei Q. Data Envelopment Analysis 2004 Beijing Science Press 7 Charnes A. Cooper W. W. Rhodes E. L. Measuring the efficiency of decision making units European Journal of Operational Research 1978 2 6 429 444 10.1016/0377-2217(78)90138-8 2-s2.0-0018032112 8 Wang X. Establishment and practice of intensive insulin pump therapy system for diabetic patients during perioperative period Chinese Circulation Journal 2015 178 9 Xu K. Study on the effect of type 2 diabetes on perioperative nutritional support in elderly patients International Journal of Pathology and Clinical Medicine 2015 35 p. 70 10 Li Y. Zhu S. Gao Z. Application of insulin analogues in the perioperative period of type 2 diabetes patients undergoing abdominal surgery Medical Innovation of China 2010 7 34 35 11 Huang T. Cao X. Ren X. Li B. Clinical application of insulin pump in perioperative period of diabetes Medical Innovation of China 2011 8 41 42 12 Ables A. Z. Bouknight P. J. Bendyk H. Beagle R. Alsip R. Williams J. Blood glucose control in noncritically ill patients is associated with a decreased length of stay, readmission rate, and hospital mortality Journal for Healthcare Quality 2016 38 6 e89 e96 10.1097/JHQ.0000000000000023 2-s2.0-85010069153 26991349 13 Li M. Shen Y. Peng L. Clinical application of 3C therapy in perioperative period of patients with pituitary growth hormone tumor and diabetes Chinese Journal of Diabetes 2017 9 446 449 14 Chinese Medical Doctor Association Endocrinology and Metabolism Physician Branch, Chinese Society of Endocrinology, Chinese Diabetes Society Chinese Insulin Pump Treatment Guidelines (2014) Guidelines for the 13th National Endocrinology Academic Conference of the Chinese Medical Association 2014 15 Freckmann G. Buck S. Waldenmaier D. Insulin pump therapy for patients with type 2 diabetes mellitus: evidence, current barriers, and new technologies Journal of Diabetes Science and Technology 2021 15 4 901 915 10.1177/1932296820928100 32476471 16 Wang Q. Deng W. Li T. Shiwen Zhu X. Sun W. X. Perioperative blood glucose management in diabetic patients with traumatic orthopedics diseases Chinese Journal of Bone and Joint Surgery 2019 12 89 93 (in Chinese) 17 Yang X. Zhou L. Liang C. Li Q. Comparing the cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily insulin injections for the treatment of patients with type 2 diabetes mellitus Chinese General Practice 2018 21 219 222 (in Chinese) 18 Huang L. Li W. Jiayuan W. Liu H. Yao C. Application of evaluation methods of health economics in clinical medicine research Guide of China Medicine 2019 17 58 60 (in Chinese) 19 Gao F. Therapeutic effect evaluation on traditional Chinese medicine regimen for early rehabilitation in ischemic stroke by data envelopment analysis 2010 10 (in Chinese) 20 Yang G. Liu W. Zheng H. Review of data envelopment analysis Journal of Systems Engineering 2013 28 840 841 (in Chinese) 21 Celikbilek C. Schwerha J. D. Benchmarking chronic diseases and prevention of U.S. states: DEA approach IIE Annual Conference Proceedings 2013 Institute of Industrial and Systems Engineers 22 Zhang Z. He Z. Chen J. Liu X. Data envelopment analysis of threetherapy schemes in the treatment of type 2 diabetes Strait The Pharmaceutical Journal 2015 27 83 85 (in Chinese) 23 Nazar H. Tsibouklis J. Towards the nasal delivery of insulin Therapeutic Delivery 2012 3 11 1241 1243 10.4155/tde.12.120 2-s2.0-84870165772 23259244 24 Djupesland P. G. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review Translational Research 2013 3 1 42 62 10.1007/s13346-012-0108-9 2-s2.0-84875516600 25 Christie C. D. Hanzal R. F. Insulin absorption by the conjunctival membranes in rabbits The Journal of Clinical Investigation 1931 10 4 787 793 10.1172/JCI100383 16694010 26 Abramson A. Caffarel-Salvador E. Soares V. A luminal unfolding microneedle injector for oral delivery of macromolecules Nature Medicine 2019 25 10 1512 1518 10.1038/s41591-019-0598-9 2-s2.0-85074196226 31591601 27 Sun Q. Li J. Gao F. New insights into insulin: the anti-inflammatory effect and its clinical relevance World Journal of Diabetes 2014 5 2 89 89 10.4239/wjd.v5.i2.89 24765237 28 Zhang S. Kim K. H. TNF-α inhibits glucose-induced insulin secretion in a pancreatic β-cell line (INS-1) FEBS Letters 1995 377 2 237 239 10.1016/0014-5793(95)01272-9 2-s2.0-0029417129 8543058 29 Tsai S. Clemente-Casares X. Zhou A. C. Insulin receptor-mediated stimulation boosts t cell immunity during inflammation and infection Cell Metabolism 2018 28 6 922 934.e4 10.1016/j.cmet.2018.08.003 2-s2.0-85058542831 30174303